Cell MedX Corp.

Equities

CMXC

US15115X1072

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:27:57 2024-07-03 EDT			5-day change	1st Jan Change
0.024 ^USD	+4.35%		+4.35%	+9.09%

04-15	Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	CI
03-12	Cell MedX Corp. announced that it has received $0.075 million in funding	CI

Cell Medx Corp. Reports Earnings Results for the Second Quarter Ended November 30, 2019

January 14, 2020 at 03:17 pm

Cell MedX Corp. announced earnings results for the second quarter ended November 30, 2019. For the second quarter, the company announced sales was USD 757 compared to USD 0 a year ago. Net loss was USD 303,488 compared to USD 127,517 a year ago. Basic loss per share was USD 0.01 compared to Basic EPS of USD 0 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to Basic EPS - Continuing Operations of USD 0 a year ago. For the half year, sales was USD 12,100 compared to USD 0 a year ago. Net loss was USD 548,775 compared to USD 370,982 a year ago. Basic loss per share was USD 0.01 compared to USD 0.01 a year ago.

Latest news about Cell MedX Corp.

Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	04-15	CI
Cell MedX Corp. announced that it has received $0.075 million in funding	03-11	CI
Cell Medx Corp. Announces Resignation of Brad Hargreaves from the Board of Directors	02-27	CI
Cell MedX Corp. Appoints George Adams as Chairman of the Board	02-25	CI
Cell MedX Corp. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	01-16	CI
Cell MedX Corp. Announces Chief Executive Officer Changes	12-19	CI
Cell MedX Corp. Announces Board Appointments	12-19	CI
Cell MedX Corp. Announces Board Changes	11-09	CI
Cell MedX Corp. Reports Earnings Results for the First Quarter Ended August 31, 2023	23-10-16	CI
Cell MedX Corp. Reports Earnings Results for the Full Year Ended May 31, 2023	23-09-01	CI
Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	23-06-29	CI
Cell MedX Corp. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022	23-05-19	CI
Cell MedX Corp. Reports Earnings Results for the First Quarter Ended August 31, 2022	23-04-19	CI
Cell MedX Corp. Reports Earnings Results for the Full Year Ended May 31, 2022	23-04-07	CI
Cell MedX Corp. Auditor Raises 'Going Concern' Doubt	23-04-06	CI
Cell MedX Corp. Appoints Dwayne Yaretz as Chief Executive Officer Replacing Frank McEnulty	22-04-27	CI
Cell Medx Corp Appoints Dwayne Yaretz to the Board of Directors	22-04-27	CI
Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022	22-04-11	CI
Cell MedX Corp. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2021	22-01-12	CI
Cell MedX Corp. Announces FDA Commences Review of Cell MedX's Premarket Notification and Health Canada Renews Class II Medical Device Licenses for Ebalance(R) Systems	21-11-15	CI
Cell Medx Corp. Reports Earnings Results for the First Quarter Ended August 31, 2021	21-10-14	CI
Cell MedX Corp. Files Premarket Notification with the US Food and Drug Administration	21-09-17	CI
Cell Medx Corp. Reports Earnings Results for the Full Year Ended May 31, 2021	21-08-30	CI
Cell MedX Corp. Auditor Raises 'Going Concern' Doubt	21-08-29	CI
Cell MedX Corp. Reports Earnings Results for the Third Quarter Ended February 28, 2021	21-04-09	CI

Chart Cell MedX Corp.

Duration

Period

More charts

Company Profile

Cell MedX Corp. is a biotechnology company. It is focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, general health, pain relief, wellness and alleviate complications associated with medical conditions including, diabetes, Parkinsonâs disease, high blood pressure, neuropathy, and kidney function. The Company, through its subsidiary, is engaged in developing and manufacturing therapeutic devices based on its eBalance technology, which harnesses the power of microcurrents and its effects on the human body. The eBalance Pro System and eBalance Home System, are microcurrent electrotherapy systems intended to administer a specific variety of therapeutic microcurrent algorithms for temporary relief of pain associated with sore/aching muscles in the shoulders, waist, back, neck, upper extremities (arms) and lower extremities. Its Microcurrent therapy uses molecular bioelectricity in cell-to-cell signaling.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELL MEDX CORP.	+9.09%	7.13M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research